Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2636771 and Pembrolizumab in Metastatic Melanoma with PTEN Loss
NCT03131908Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2017
- Primary completion
- Aug 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of GSK-2636771 in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2017; status: completed.
02
Drugs
GSK-2636771
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03131908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131908.